Aarti Pharmalabs Limited has informed the Exchange regarding Outcome of Board Meeting held on May 10, 2025.
AARTIPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Aarti Pharmalabs announced audited financial results for Q4 and FY ended March 31, 2025. Standalone revenue from operations rose to Rs. 1,771 crore (up ~18% YoY from Rs. 1,502 crore), while standalone net profit grew ~28% to Rs. 257 crore from Rs. 201 crore. Consolidated revenue rose to Rs. 2,115 crore (up ~14% YoY) and consolidated net profit rose ~26% to Rs. 272 crore. The Board recommended a dividend of Rs. 2.50 per share (50% on Rs. 5 face value), subject to AGM approval. The statutory auditor issued an unmodified (clean) opinion on both standalone and consolidated results. The Board also appointed a Cost Auditor and an Internal Auditor for FY 2025-26.
Strong profit growth, healthy dividend, and a clean audit report are positive signals for shareholders; the FY25 performance reflects solid operating momentum and margin improvement, which should be supportive of the stock.